Here, we demonstrate that LRH‐1 and its inhibitor SHP (Small Heterodimer Partner, NR0B2) are critically involved in the development of inflammation‐driven intestinal tumours, by regulating the initial inflammatory phase, which promotes tumour development, as well as the immune escape of established tumours. Here, NR0B2 is linked to neoplasm.